{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:58:21Z","timestamp":1791187101489,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,2,25]],"date-time":"2014-02-25T00:00:00Z","timestamp":1393286400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s00259-014-2724-8","type":"journal-article","created":{"date-parts":[[2014,2,24]],"date-time":"2014-02-24T11:42:35Z","timestamp":1393242155000},"page":"1210-1220","source":"Crossref","is-referenced-by-count":39,"title":["Cross sectional PET study of cerebral adenosine A1 receptors in premanifest and manifest Huntington\u2019s disease"],"prefix":"10.1007","volume":"41","author":[{"given":"Andreas","family":"Matusch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Saft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Elmenhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter H.","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,25]]},"reference":[{"issue":"2","key":"2724_CR1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ajmg.b.30992","volume":"153B","author":"DR Langbehn","year":"2010","unstructured":"Langbehn DR, Hayden MR, Paulsen JS. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet. 2010;153B(2):397\u2013408. doi: 10.1002\/ajmg.b.30992 .","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"5","key":"2724_CR2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/1531-8249(200005)47:5<644::AID-ANA13>3.0.CO;2-C","volume":"47","author":"G Kunig","year":"2000","unstructured":"Kunig G, Leenders KL, Sanchez-Pernaute R, Antonini A, Vontobel P, Verhagen A, et al. Benzodiazepine receptor binding in Huntington\u2032s disease: [11C]flumazenil uptake measured using positron emission tomography. Ann Neurol. 2000;47(5):644\u20138.","journal-title":"Ann Neurol"},{"issue":"Pt 11","key":"2724_CR3","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1093\/brain\/awm217","volume":"130","author":"A Feigin","year":"2007","unstructured":"Feigin A, Tang C, Ma Y, Mattis P, Zgaljardic D, Guttman M, et al. Thalamic metabolism and symptom onset in preclinical Huntington\u2019s disease. Brain. 2007;130(Pt 11):2858\u201367. doi: 10.1093\/brain\/awm217 .","journal-title":"Brain"},{"issue":"6","key":"2724_CR4","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1007\/s00259-012-2114-z","volume":"39","author":"A Ciarmiello","year":"2012","unstructured":"Ciarmiello A, Giovacchini G, Orobello S, Bruselli L, Elifani F, Squitieri F. 18\u00a0F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size. Eur J Nucl Med Mol Imaging. 2012;39(6):1030\u20136. doi: 10.1007\/s00259-012-2114-z .","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Pt 7","key":"2724_CR5","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/brain\/awm044","volume":"130","author":"YF Tai","year":"2007","unstructured":"Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, et al. Microglial activation in presymptomatic Huntington\u2019s disease gene carriers. Brain. 2007;130(Pt 7):1759\u201366. doi: 10.1093\/brain\/awm044 .","journal-title":"Brain"},{"issue":"Pt 3","key":"2724_CR6","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/brain\/120.3.503","volume":"120","author":"N Ginovart","year":"1997","unstructured":"Ginovart N, Lundin A, Farde L, Halldin C, Backman L, Swahn CG, et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington\u2019s disease. Brain. 1997;120(Pt 3):503\u201314.","journal-title":"Brain"},{"issue":"Pt 12","key":"2724_CR7","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1093\/brain\/122.12.2353","volume":"122","author":"TC Andrews","year":"1999","unstructured":"Andrews TC, Weeks RA, Turjanski N, Gunn RN, Watkins LH, Sahakian B, et al. Huntington\u2019s disease progression. PET and clinical observations. Brain. 1999;122(Pt 12):2353\u201363.","journal-title":"Brain"},{"issue":"Pt 5","key":"2724_CR8","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/brain\/awg119","volume":"126","author":"N Pavese","year":"2003","unstructured":"Pavese N, Andrews TC, Brooks DJ, Ho AK, Rosser AE, Barker RA, et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington\u2019s disease: a PET study. Brain. 2003;126(Pt 5):1127\u201335.","journal-title":"Brain"},{"issue":"3 Suppl","key":"2724_CR9","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1017\/S0317167100037896","volume":"14","author":"WR Martin","year":"1987","unstructured":"Martin WR, Hayden MR. Cerebral glucose and dopa metabolism in movement disorders. Can J Neurol Sci. 1987;14(3 Suppl):448\u201351.","journal-title":"Can J Neurol Sci"},{"issue":"9","key":"2724_CR10","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1212\/WNL.54.9.1753","volume":"54","author":"NI Bohnen","year":"2000","unstructured":"Bohnen NI, Koeppe RA, Meyer P, Ficaro E, Wernette K, Kilbourn MR, et al. Decreased striatal monoaminergic terminals in Huntington disease. Neurology. 2000;54(9):1753\u20139.","journal-title":"Neurology"},{"issue":"4","key":"2724_CR11","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1053-8119(03)00241-6","volume":"19","author":"A Bauer","year":"2003","unstructured":"Bauer A, Holschbach MH, Meyer PT, Boy C, Herzog H, Olsson RA, et al. In vivo imaging of adenosine A1 receptors in the human brain with [18\u00a0F]CPFPX and positron emission tomography. Neuroimage. 2003;19(4):1760\u20139.","journal-title":"Neuroimage"},{"issue":"23","key":"2724_CR12","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1021\/jm020905i","volume":"45","author":"MH Holschbach","year":"2002","unstructured":"Holschbach MH, Olsson RA, Bier D, Wutz W, Sihver W, Schuller M, et al. Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[(18)F]fluoropropyl)-1-propylxanthine ([(18)F]CPFPX): a potent and selective A(1)-adenosine receptor antagonist for in vivo imaging. J Med Chem. 2002;45(23):5150\u20136.","journal-title":"J Med Chem"},{"issue":"9","key":"2724_CR13","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1523\/JNEUROSCI.5066-06.2007","volume":"27","author":"D Elmenhorst","year":"2007","unstructured":"Elmenhorst D, Meyer PT, Winz OH, Matusch A, Ermert J, Coenen HH, et al. Sleep deprivation increases A1 adenosine receptor binding in the human brain: a positron emission tomography study. J Neurosci. 2007;27(9):2410\u20135. doi: 10.1523\/JNEUROSCI.5066-06.2007 .","journal-title":"J Neurosci"},{"issue":"12","key":"2724_CR14","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.neurobiolaging.2006.08.005","volume":"28","author":"PT Meyer","year":"2007","unstructured":"Meyer PT, Elmenhorst D, Boy C, Winz O, Matusch A, Zilles K, et al. Effect of aging on cerebral A1 adenosine receptors: A [18\u00a0F]CPFPX PET study in humans. Neurobiol Aging. 2007;28(12):1914\u201324. doi: 10.1016\/j.neurobiolaging.2006.08.005 .","journal-title":"Neurobiol Aging"},{"issue":"2","key":"2724_CR15","first-page":"200","volume":"47","author":"PT Meyer","year":"2006","unstructured":"Meyer PT, Elmenhorst D, Matusch A, Winz O, Zilles K, Bauer A. 18\u00a0F-CPFPX PET: on the generation of parametric images and the effect of scan duration. J Nucl Med. 2006;47(2):200\u20137.","journal-title":"J Nucl Med"},{"issue":"7","key":"2724_CR16","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/sj.cdd.4402132","volume":"14","author":"BB Fredholm","year":"2007","unstructured":"Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ. 2007;14(7):1315\u201323. doi: 10.1038\/sj.cdd.4402132 .","journal-title":"Cell Death Differ"},{"issue":"6","key":"2724_CR17","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1474-4422(03)00411-3","volume":"2","author":"D Blum","year":"2003","unstructured":"Blum D, Hourez R, Galas MC, Popoli P, Schiffmann SN. Adenosine receptors and Huntington\u2019s disease: implications for pathogenesis and therapeutics. Lancet Neurol. 2003;2(6):366\u201374.","journal-title":"Lancet Neurol"},{"issue":"1","key":"2724_CR18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.nbd.2004.05.008","volume":"17","author":"M Gianfriddo","year":"2004","unstructured":"Gianfriddo M, Melani A, Turchi D, Giovannini MG, Pedata F. Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow. Neurobiol Dis. 2004;17(1):77\u201388.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"2724_CR19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bbadis.2009.07.012","volume":"1802","author":"M Damiano","year":"2010","unstructured":"Damiano M, Galvan L, Deglon N, Brouillet E. Mitochondria in Huntington\u2019s disease. Biochim Biophys Acta. 2010;1802(1):52\u201361. doi: 10.1016\/j.bbadis.2009.07.012 .","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"2724_CR20","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1471-4159.2005.03169.x","volume":"94","author":"A Bauer","year":"2005","unstructured":"Bauer A, Zilles K, Matusch A, Holzmann C, Riess O, von Horsten S. Regional and subtype selective changes of neurotransmitter receptor density in a rat transgenic for the Huntington\u2019s disease mutation. J Neurochem. 2005;94(3):639\u201350. doi: 10.1111\/j.1471-4159.2005.03169.x .","journal-title":"J Neurochem"},{"issue":"5","key":"2724_CR21","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/ana.410410521","volume":"41","author":"JB Penney Jr","year":"1997","unstructured":"Penney Jr JB, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington\u2019s disease. Ann Neurol. 1997;41(5):689\u201392. doi: 10.1002\/ana.410410521 .","journal-title":"Ann Neurol"},{"issue":"2","key":"2724_CR22","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"HuntigtonStudyGroup","year":"1996","unstructured":"HuntigtonStudyGroup. Unified Huntington\u2019s Disease Rating Scale: reliability and consistency. Mov Disord. 1996;11(2):136\u201342. doi: 10.1002\/mds.870110204 .","journal-title":"Mov Disord"},{"issue":"8","key":"2724_CR23","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/mds.20939","volume":"21","author":"C Saft","year":"2006","unstructured":"Saft C, Andrich J, Meisel NM, Przuntek H, Muller T. Assessment of simple movements reflects impairment in Huntington\u2019s disease. Mov Disord. 2006;21(8):1208\u201312. doi: 10.1002\/mds.20939 .","journal-title":"Mov Disord"},{"issue":"5","key":"2724_CR24","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.neuropsychologia.2007.12.002","volume":"46","author":"C Saft","year":"2008","unstructured":"Saft C, Schuttke A, Beste C, Andrich J, Heindel W, Pfleiderer B. fMRI reveals altered auditory processing in manifest and premanifest Huntington\u2019s disease. Neuropsychologia. 2008;46(5):1279\u201389. doi: 10.1016\/j.neuropsychologia.2007.12.002 .","journal-title":"Neuropsychologia"},{"issue":"4","key":"2724_CR25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00213-007-0921-x","volume":"195","author":"R Hurlemann","year":"2008","unstructured":"Hurlemann R, Matusch A, Kuhn KU, Berning J, Elmenhorst D, Winz O, et al. 5-HT2A receptor density is decreased in the at-risk mental state. Psychopharmacology (Berl). 2008;195(4):579\u201390. doi: 10.1007\/s00213-007-0921-x .","journal-title":"Psychopharmacology (Berl)."},{"issue":"6","key":"2724_CR26","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1212\/01.wnl.0000176071.08694.cc","volume":"65","author":"JC Oostrom van","year":"2005","unstructured":"van Oostrom JC, Maguire RP, Verschuuren-Bemelmans CC, van der Veenma Duin L, Pruim J, Roos RA, et al. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. Neurology. 2005;65(6):941\u20133.","journal-title":"Neurology"},{"issue":"1","key":"2724_CR27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","volume":"11","author":"SJ Tabrizi","year":"2012","unstructured":"Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, et al. Potential endpoints for clinical trials in premanifest and early Huntington\u2019s disease in the TRACK-HD study: analysis of 24\u00a0month observational data. Lancet Neurol. 2012;11(1):42\u201353. doi: 10.1016\/S1474-4422(11)70263-0 .","journal-title":"Lancet Neurol"},{"issue":"15","key":"2724_CR28","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/hmg\/ddm133","volume":"16","author":"A Kuhn","year":"2007","unstructured":"Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, et al. Mutant huntingtin\u2019s effects on striatal gene expression in mice recapitulate changes observed in human Huntington\u2019s disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet. 2007;16(15):1845\u201361.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"2724_CR29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1124\/mol.53.1.43","volume":"53","author":"H Ren","year":"1998","unstructured":"Ren H, Stiles GL. A single-stranded DNA binding site in the human A1 adenosine receptor gene promoter. Mol Pharmacol. 1998;53(1):43\u201351.","journal-title":"Mol Pharmacol"},{"issue":"20","key":"2724_CR30","doi-asserted-by":"crossref","first-page":"14204","DOI":"10.1074\/jbc.274.20.14204","volume":"274","author":"SA Rivkees","year":"1999","unstructured":"Rivkees SA, Chen M, Kulkarni J, Browne J, Zhao Z. Characterization of the murine A1 adenosine receptor promoter, potent regulation by GATA-4 and Nkx2.5. J Biol Chem. 1999;274(20):14204\u20139.","journal-title":"J Biol Chem"},{"issue":"31","key":"2724_CR31","doi-asserted-by":"crossref","first-page":"11023","DOI":"10.1073\/pnas.0504921102","volume":"102","author":"F Borovecki","year":"2005","unstructured":"Borovecki F, Lovrecic L, Zhou J, Jeong H, Then F, Rosas HD, et al. Genome-wide expression profiling of human blood reveals biomarkers for Huntington\u2019s disease. Proc Natl Acad Sci U S A. 2005;102(31):11023\u20138. doi: 10.1073\/pnas.0504921102 .","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2724_CR32","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1084\/jem.20050177","volume":"202","author":"HK Eltzschig","year":"2005","unstructured":"Eltzschig HK, Abdulla P, Hoffman E, Hamilton KE, Daniels D, Schonfeld C, et al. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J Exp Med. 2005;202(11):1493\u2013505. doi: 10.1084\/jem.20050177 .","journal-title":"J Exp Med"},{"issue":"1\u20132","key":"2724_CR33","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.brainres.2005.01.029","volume":"1039","author":"L Kennedy","year":"2005","unstructured":"Kennedy L, Shelbourne PF, Dewar D. Alterations in dopamine and benzodiazepine receptor binding precede overt neuronal pathology in mice modelling early Huntington disease pathogenesis. Brain Res. 2005;1039(1\u20132):14\u201321. doi: 10.1016\/j.brainres.2005.01.029 .","journal-title":"Brain Res"},{"issue":"1","key":"2724_CR34","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.nbd.2006.01.014","volume":"23","author":"A Tarditi","year":"2006","unstructured":"Tarditi A, Camurri A, Varani K, Borea PA, Woodman B, Bates G, et al. Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease. Neurobiol Dis. 2006;23(1):44\u201353. doi: 10.1016\/j.nbd.2006.01.014 .","journal-title":"Neurobiol Dis"},{"issue":"2","key":"2724_CR35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0197-0186(96)00055-1","volume":"30","author":"DJ Doolette","year":"1997","unstructured":"Doolette DJ. Mechanism of adenosine accumulation in the hippocampal slice during energy deprivation. Neurochem Int. 1997;30(2):211\u201323.","journal-title":"Neurochem Int"},{"issue":"3","key":"2724_CR36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0304-3940(00)01643-8","volume":"297","author":"M Schindler","year":"2001","unstructured":"Schindler M, Harris CA, Hayes B, Papotti M, Humphrey PP. Immunohistochemical localization of adenosine A1 receptors in human brain regions. Neurosci Lett. 2001;297(3):211\u20135.","journal-title":"Neurosci Lett"},{"issue":"2","key":"2724_CR37","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0006-8993(95)00062-U","volume":"677","author":"SA Rivkees","year":"1995","unstructured":"Rivkees SA, Price SL, Zhou FC. Immunohistochemical detection of A1 adenosine receptors in rat brain with emphasis on localization in the hippocampal formation, cerebral cortex, cerebellum, and basal ganglia. Brain Res. 1995;677(2):193\u2013203.","journal-title":"Brain Res"},{"issue":"5","key":"2724_CR38","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ana.1007","volume":"49","author":"JB Johnston","year":"2001","unstructured":"Johnston JB, Silva C, Gonzalez G, Holden J, Warren KG, Metz LM, et al. Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Ann Neurol. 2001;49(5):650\u20138.","journal-title":"Ann Neurol"},{"issue":"1","key":"2724_CR39","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.neubiorev.2011.06.002","volume":"36","author":"SM Henley","year":"2012","unstructured":"Henley SM, Novak MJ, Frost C, King J, Tabrizi SJ, Warren JD. Emotion recognition in Huntington\u2019s disease: a systematic review. Neurosci Biobehav Rev. 2012;36(1):237\u201353. doi: 10.1016\/j.neubiorev.2011.06.002 .","journal-title":"Neurosci Biobehav Rev"},{"issue":"3","key":"2724_CR40","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.psychres.2011.04.007","volume":"188","author":"R Ille","year":"2011","unstructured":"Ille R, Holl AK, Kapfhammer HP, Reisinger K, Schafer A, Schienle A. Emotion recognition and experience in Huntington\u2019s disease: is there a differential impairment? Psychiatry Res. 2011;188(3):377\u201382. doi: 10.1016\/j.psychres.2011.04.007 .","journal-title":"Psychiatry Res"},{"issue":"45","key":"2724_CR41","doi-asserted-by":"crossref","first-page":"11695","DOI":"10.1523\/JNEUROSCI.2659-08.2008","volume":"28","author":"C Beste","year":"2008","unstructured":"Beste C, Saft C, Gunturkun O, Falkenstein M. Increased cognitive functioning in symptomatic Huntington\u2019s disease as revealed by behavioral and event-related potential indices of auditory sensory memory and attention. J Neurosci. 2008;28(45):11695\u2013702. doi: 10.1523\/JNEUROSCI.2659-08.2008 .","journal-title":"J Neurosci"},{"key":"2724_CR42","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.nbd.2013.05.013","volume":"58","author":"C Simonin","year":"2013","unstructured":"Simonin C, Duru C, Salleron J, Hincker P, Charles P, Delval A, et al. Association between caffeine intake and age at onset in Huntington\u2019s disease. Neurobiol Dis. 2013;58:179\u201382. doi: 10.1016\/j.nbd.2013.05.013 .","journal-title":"Neurobiol Dis"},{"issue":"34","key":"2724_CR43","doi-asserted-by":"crossref","first-page":"10982","DOI":"10.1523\/JNEUROSCI.23-34-10982.2003","volume":"23","author":"PD Alfinito","year":"2003","unstructured":"Alfinito PD, Wang SP, Manzino L, Rijhsinghani S, Zeevalk GD, Sonsalla PK. Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. J Neurosci. 2003;23(34):10982\u20137.","journal-title":"J Neurosci"},{"issue":"6","key":"2724_CR44","doi-asserted-by":"crossref","first-page":"e20934","DOI":"10.1371\/journal.pone.0020934","volume":"6","author":"NK Huang","year":"2011","unstructured":"Huang NK, Lin JH, Lin JT, Lin CI, Liu EM, Lin CJ, et al. A new drug design targeting the adenosinergic system for Huntington\u2019s disease. PLoS One. 2011;6(6):e20934. doi: 10.1371\/journal.pone.0020934 .","journal-title":"PLoS One"},{"issue":"4","key":"2724_CR45","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","volume":"65","author":"DR Langbehn","year":"2004","unstructured":"Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington\u2019s disease based on CAG length. Clin Genet. 2004;65(4):267\u201377. doi: 10.1111\/j.1399-0004.2004 .","journal-title":"Clin Genet"},{"key":"2724_CR46","doi-asserted-by":"crossref","unstructured":"Saft C, Andrich J, Meisel NM, Przuntek H, M\u00fcller T. Assessment of complex movements reflects dysfunction in Huntington's disease. J Neurol. 2003;250(12):1469\u201374. doi: 10.1007\/s00415-003-0256-4 .","DOI":"10.1007\/s00415-003-0256-4"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-014-2724-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-014-2724-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-014-2724-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T22:35:31Z","timestamp":1565217331000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-014-2724-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,25]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["2724"],"URL":"https:\/\/doi.org\/10.1007\/s00259-014-2724-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,25]]}}}